Article
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Hepatology (Baltimore, Md.) - 1 Apr 2017
Kowdley Kris V, Sundaram Vinay, Jeon Christie Y, Qureshi Kamran, Latt Nyan L, Sahota Amandeep, Lott Stephen, Curry Michael P, Tsai Naoky, Chaiyakunapruk Nathorn, Lee Yoori, Petersen Jorg, Buggisch Peter
Abstract excerpt
Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.